Isoniazid-resistant Tuberculosis: a Cause for Concern?

Overview

Journal Int J Tuberc Lung Dis

Specialty Pulmonary Medicine

Date 2017 Feb 25

PMID 28234075

Citations 41

Authors

H R Stagg

M C Lipman

T D McHugh

H E Jenkins

Affiliations

Soon will be listed here.

Abstract

The drug isoniazid (INH) is a key component of global tuberculosis (TB) control programmes. It is estimated, however, that 16.1% of TB disease cases in the former Soviet Union countries and 7.5% of cases outside of these settings have non-multidrug-resistant (MDR) INH resistance. Resistance has been linked to poorer treatment outcomes, post-treatment relapse and death, at least for specific sites of disease. Multiple genetic loci are associated with phenotypic resistance; however, the relationship between genotype and phenotype is complex, and restricts the use of rapid sequencing techniques as part of the diagnostic process to determine the most appropriate treatment regimens for patients. The burden of resistance also influences the usefulness of INH preventive therapy. Despite seven decades of INH use, our knowledge in key areas such as the epidemiology of resistant strains, their clinical consequences, whether tailored treatment regimens are required and the role of INH resistance in fuelling the MDR-TB epidemic is limited. The importance of non-MDR INH resistance needs to be re-evaluated both globally and by national TB control programmes.

Citing Articles

Differential Host Gene Expression in Response to Infection by Different Strains-A Pilot Study.

Megawati D, Armitige L, Tazi L Microorganisms. 2024; 12(11).

PMID: 39597535 PMC: 11596623. DOI: 10.3390/microorganisms12112146.

Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis.

Encinas L, Li S, Rullas-Trincado J, Tasneen R, Tyagi S, Soni H Antimicrob Agents Chemother. 2024; 68(11):e0035724.

PMID: 39345183 PMC: 11539229. DOI: 10.1128/aac.00357-24.

Incidence, Outcomes, and Risk Factors for Isoniazid-Resistant Tuberculosis from 2012 to 2022 in Eastern China.

Shao Y, Song W, Song H, Li G, Zhu L, Liu Q Antibiotics (Basel). 2024; 13(4).

PMID: 38667054 PMC: 11047343. DOI: 10.3390/antibiotics13040378.

Multi-Drug Resistance Tuberculosis (MDR-TB) Challenges in India: A Review.

Vishwakarma D, Gaidhane A, Sahu S, Rathod A Cureus. 2024; 15(12):e50222.

PMID: 38192967 PMC: 10772311. DOI: 10.7759/cureus.50222.

Drug resistance and the genotypic characteristics of rpoB and katG in rifampicin- and/or isoniazid-resistant Mycobacterium tuberculosis isolates in central Vietnam.

Nguyen T, Nguyen T, Truong V, Tran T, Phan V, Nguyen T Osong Public Health Res Perspect. 2023; 14(5):347-355.

PMID: 37920892 PMC: 10626318. DOI: 10.24171/j.phrp.2023.0124.

References

. Controlled clinical trial of two 6-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Tanzania/British Medical Research Council Study. Am Rev Respir Dis. 1985; 131(5):727-31. DOI: 10.1164/arrd.1985.131.5.727. View

Smith S, Kurbatova E, Cavanaugh J, Cegielski J . Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis. Int J Tuberc Lung Dis. 2011; 16(2):203-5. PMC: 4593497. DOI: 10.5588/ijtld.11.0445. View

Menzies D, Benedetti A, Paydar A, Martin I, Royce S, Pai M . Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med. 2009; 6(9):e1000146. PMC: 2736385. DOI: 10.1371/journal.pmed.1000146. View

Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W . Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med. 2010; 6(9):e1000150. PMC: 2736403. DOI: 10.1371/journal.pmed.1000150. View

Abate D, Tedla Y, Meressa D, Ameni G . Isoniazid and rifampicin resistance mutations and their effect on second-line anti-tuberculosis treatment. Int J Tuberc Lung Dis. 2014; 18(8):946-51. DOI: 10.5588/ijtld.13.0926. View

Hatherell H, Colijn C, Stagg H, Jackson C, Winter J, Abubakar I . Interpreting whole genome sequencing for investigating tuberculosis transmission: a systematic review. BMC Med. 2016; 14:21. PMC: 4804562. DOI: 10.1186/s12916-016-0566-x. View

Jeeves R, Marriott A, Pullan S, Hatch K, Allnutt J, Freire-Martin I . Mycobacterium tuberculosis Is Resistant to Isoniazid at a Slow Growth Rate by Single Nucleotide Polymorphisms in katG Codon Ser315. PLoS One. 2015; 10(9):e0138253. PMC: 4575197. DOI: 10.1371/journal.pone.0138253. View

Fenner L, Egger M, Bodmer T, Altpeter E, Zwahlen M, Jaton K . Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2012; 56(6):3047-53. PMC: 3370767. DOI: 10.1128/AAC.06460-11. View

OSullivan D, McHugh T, Gillespie S . Mapping the fitness of Mycobacterium tuberculosis strains: a complex picture. J Med Microbiol. 2010; 59(Pt 12):1533-1535. DOI: 10.1099/jmm.0.019091-0. View

10.

Wang T, Lin S, Shie S, Chou P, Huang C, Chung F . Clinical characteristics and treatment outcomes of patients with low- and high-concentration isoniazid-monoresistant tuberculosis. PLoS One. 2014; 9(1):e86316. PMC: 3899226. DOI: 10.1371/journal.pone.0086316. View

11.

Zierski M, BEK E, Long M, Snider Jr D . Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment. Am Rev Respir Dis. 1980; 122(6):879-89. DOI: 10.1164/arrd.1980.122.6.879. View

12.

Polesky A, Farber H, Gottlieb D, Park H, Levinson S, OCONNELL J . Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med. 1996; 154(5):1473-7. DOI: 10.1164/ajrccm.154.5.8912767. View

13.

LoBue P, Moser K . Isoniazid- and rifampin-resistant tuberculosis in San Diego County, California, United States, 1993-2002. Int J Tuberc Lung Dis. 2005; 9(5):501-6. View

14.

Deepa D, Achanta S, Jaju J, Rao K, Samyukta R, Claassens M . The impact of isoniazid resistance on the treatment outcomes of smear positive re-treatment tuberculosis patients in the state of Andhra Pradesh, India. PLoS One. 2013; 8(10):e76189. PMC: 3795751. DOI: 10.1371/journal.pone.0076189. View

15.

Dominguez J, Boettger E, Cirillo D, Cobelens F, Eisenach K, Gagneux S . Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement. Int J Tuberc Lung Dis. 2015; 20(1):24-42. DOI: 10.5588/ijtld.15.0221. View

16.

Cohen T, Becerra M, Murray M . Isoniazid resistance and the future of drug-resistant tuberculosis. Microb Drug Resist. 2005; 10(4):280-5. PMC: 2652757. DOI: 10.1089/mdr.2004.10.280. View

17.

Casali N, Nikolayevskyy V, Balabanova Y, Harris S, Ignatyeva O, Kontsevaya I . Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet. 2014; 46(3):279-86. PMC: 3939361. DOI: 10.1038/ng.2878. View

18.

Hazbon M, Brimacombe M, Bobadilla Del Valle M, Cavatore M, Guerrero M, Varma-Basil M . Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2006; 50(8):2640-9. PMC: 1538650. DOI: 10.1128/AAC.00112-06. View

19.

LINCOLN E . The effect of antimicrobial therapy on the prognosis of primary tuberculosis in children. Am Rev Tuberc. 1954; 69(5):682-9. DOI: 10.1164/art.1954.69.5.682. View

20.

Huyen M, Cobelens F, Buu T, Lan N, Dung N, Kremer K . Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes. Antimicrob Agents Chemother. 2013; 57(8):3620-7. PMC: 3719713. DOI: 10.1128/AAC.00077-13. View